Lundbeckfond Invest A/S - Nov 2, 2023 Form 3 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role: 10%+ Owner
Signature: /s/ Christian E. Elling, Managing Partner and /s/ Lene Skole, CEO
Stock symbol: LXEO
Transactions as of: Nov 2, 2023
Transactions value $: $0
Form type: 3
Date filed: 11/2/2023, 09:37 PM
Previous filing: Aug 11, 2023
Next filing: Nov 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	LXEO	Series A convertible preferred stock							Nov 2, 2023	Common Stock	1.32M		Direct	F1
holding	LXEO	Series B convertible preferred stock							Nov 2, 2023	Common Stock	247K		Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A convertible preferred stock is convertible into Common Stock on a 1-for-10.594230 basis at any time at the Reporting Person's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date.
F2	Each share of Series B convertible preferred stock is convertible into Common Stock on a 1-for-10.594230 basis at any time at the Reporting Person's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. Excludes shares of Common Stock issuable upon the closing of the Issuer's initial public offering pursuant to anti-dilution adjustment provisions of the Series B convertible preferred stock. The shares have no expiration date.

Content

Each share of Series A convertible preferred stock is convertible into Common Stock on a 1-for-10.594230 basis at any time at the Reporting Person's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date.

Each share of Series B convertible preferred stock is convertible into Common Stock on a 1-for-10.594230 basis at any time at the Reporting Person's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. Excludes shares of Common Stock issuable upon the closing of the Issuer's initial public offering pursuant to anti-dilution adjustment provisions of the Series B convertible preferred stock. The shares have no expiration date.